Press Releases

02.27.2026

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

02.24.2026

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

02.23.2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

02.17.2026

Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

02.06.2026

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

02.05.2026

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

02.03.2026

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

02.03.2026

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

01.10.2026

Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer

01.05.2026

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

12.18.2025

Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts

12.17.2025

PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility